Achievements

Intro text: 

Several of BIG’s trials and programmes are considered to be landmark, introducing particularly innovative designs, contributing to significant breakthroughs, or paving the way towards more personalised treatment of the disease.

Content: 

 

 

The international randomised SOFT & TEXT clinical trials offer a new post-operative treatment option for young women with hormone-sensitive early breast cancer. 

Learn more here

Content: 

 

The APHINITY trial found that adjuvant pertuzumab in combination with trastuzumab and chemotherapy in patients was better than standard treatment and reduced the risk of breast cancer recurrence or death by 19%.

 

Learn more here.

Content: 

 

 

The MINDACT trial found that 46% of patients identified as high-risk for cancer recurrence based on traditional factors were identified as lowrisk when adding the MammaPrint test. It represents a large academic effort towards de-escalating therapies.

Learn more here.

Content: 

 

The ALTTO and NeoALTTO trials represent a valuable resource for translational research as well as large scale academic collaboration. 

Learn more here.

 

Content: 

 

The HERA trial indicated that one eyar of treatment with trastuzumab had a significant and sustained benefit in preventing cancer recurrence, thus settning a new standard treatment for HER+ breast cancer.

Learn more here.

Content: 

 

 

The BIG 1-97, BIG 2-97 and BIG 1-98 trials contributed to the body of evidence that aromatase inhibitors could be used as a safe alternative to tamoxifen.

Learn more here.